[AERI] Aerie Pharmaceuticals, Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 38.65 Change: 1.45 (3.9%)
Ext. hours: Change: 0 (0%)

chart AERI

Refresh chart

Strongest Trends Summary For AERI

AERI is in the medium-term down -56% below S&P in 1 year. In the long-term down -68% below S&P in 2 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, is focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product candidate, Rhopressa, is a once-daily triple-action eye drop, which demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in a Phase 2b clinical trial. The company is conducting two Phase 3 registration trials in the U.S. to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol, as well as commencing a third safety-only Phase 3 registration trial of Rhopressa in Canada. It also develops once-daily quadruple-action Roclatan, a single drop combination of Rhopressa with latanoprost, which has completed a 28-day Phase 2b clinical trial. In addition, the company is taking preparatory steps for Phase 3 registration trials for Roclatan. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Bedminster, New Jersey.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-3.31 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-15.12
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-30.07% ROE-120.74% ROI
Current Ratio7.63 Quick Ratio Long Term Debt/Equity Debt Ratio0.46
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities35.07 M Cash From Investing Activities6.1 M Cash From Operating Activities-13.31 M Gross Profit
Net Profit-17.24 M Operating Profit-19.64 M Total Assets195.2 M Total Current Assets170.96 M
Total Current Liabilities22.39 M Total Debt124.19 M Total Liabilities146.58 M Total Revenue
Technical Data
High 52 week60.04 Low 52 week17.72 Last close20.28 Last change2.92%
RSI39.39 Average true range1.47 Beta1.33 Volume623.98 K
Simple moving average 20 days-0.53% Simple moving average 50 days-6.05% Simple moving average 200 days-40.58%
Performance Data
Performance Week8.28% Performance Month-14.93% Performance Quart-15.57% Performance Half-51.94%
Performance Year-63.37% Performance Year-to-date-43.82% Volatility daily4.76% Volatility weekly10.64%
Volatility monthly21.81% Volatility yearly75.54% Relative Volume235.1% Average Volume1.26 M
New High New Low


2020-06-05 11:31:03 | Aerie AERI Up 1.9% Since Last Earnings Report: Can It Continue?

2020-05-11 19:15:53 | Was The Smart Money Right About Aerie Pharmaceuticals Inc AERI?

2020-05-07 18:30:31 | Aerie Pharmaceuticals Inc AERI Q1 2020 Earnings Call Transcript

2020-05-07 16:11:49 | Edited Transcript of AERI earnings conference call or presentation 6-May-20 9:00pm GMT

2020-05-06 17:15:09 | Aerie Pharmaceuticals AERI Reports Q1 Loss, Lags Revenue Estimates

2020-05-06 16:01:00 | Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update

2020-05-06 15:00:00 | Aerie Pharmaceuticals, Inc. to Host Earnings Call

2020-05-05 07:30:00 | Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference

2020-04-29 07:30:00 | Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020

2020-04-28 12:34:04 | Aerie Pharmaceuticals AERI Expected to Beat Earnings Estimates: Should You Buy?

2020-04-13 10:01:02 | Aerie AERI Suspends Guidance Due to Coronavirus Outbreak

2020-04-09 16:01:00 | Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19

2020-04-07 07:30:00 | Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

2020-04-02 14:54:00 | Gone: Triangle public companies lose $30 billion in value during 1Q 2020

2020-03-25 10:18:19 | Healthcare Pro James Flynn Picks up These 3 Stocks on the Cheap

2020-03-21 11:30:03 | Why Is Aerie AERI Down 40.5% Since Last Earnings Report?

2020-02-27 05:19:13 | Aerie Pharmaceuticals, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates

2020-02-24 14:59:43 | Advance Auto Parts, Cree among Triangle companies hit as stocks tumble with rising concern over coronavirus

2020-02-24 07:30:00 | Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference

2020-02-21 19:39:40 | Edited Transcript of AERI earnings conference call or presentation 20-Feb-20 10:00pm GMT

2020-02-21 11:30:04 | Aerie's AERI Q4 Loss Wider Than Expected, Revenues Beat

2020-02-21 07:46:22 | The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion

2020-02-20 17:35:10 | Aerie Pharmaceuticals AERI Reports Q4 Loss, Tops Revenue Estimates

2020-02-20 16:01:00 | Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update

2020-02-20 10:50:48 | Some Market Stats In 5 Minutes

2020-02-18 06:30:00 | Aerie Pharmaceuticals Announces Appointment of Nina Ohara, PharmD, M.B.A, as Director, Marketing and Gregory Jones, CPA, as Director, Tax

2020-02-13 07:30:00 | Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 20, 2020

2020-02-12 05:13:05 | Aerie Pharmaceuticals, Inc.'s NASDAQ:AERI Path To Profitability

2020-02-03 06:30:00 | Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, Ph.D., as Vice President, Clinical Development and Medical Affairs

2020-01-21 06:30:00 | Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan® netarsudil and latanoprost ophthalmic solution 0.02%/0.005%

2020-01-08 17:18:01 | How Did Aerie Pharmaceuticals Inc AERI Perform In Comparison to Hedge Fund Favorites in 2019?

2020-01-07 05:26:16 | Does Aerie Pharmaceuticals NASDAQ:AERI Have A Healthy Balance Sheet?

2020-01-03 10:04:03 | Aerie's AERI Application for Roclanda Accepted in Europe

2020-01-02 08:46:41 | The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe

2020-01-02 06:30:00 | Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® netarsudil and latanoprost ophthalmic solution 0.02%/0.005% Marketing Authorisation Application in Europe

2019-12-09 06:30:00 | Aerie Pharmaceuticals Announces Appointment of Amine Sinmazisik as Director, Finance

2019-12-06 11:31:04 | Aerie AERI Up 4.7% Since Last Earnings Report: Can It Continue?

2019-12-04 09:19:44 | Is Aerie Pharmaceuticals Inc AERI A Good Stock To Buy ?

2019-12-03 06:15:00 | Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® netarsudil and latanoprost ophthalmic solution 0.02%/0.005% in Europe

2019-12-02 04:56:18 | Did Aerie Pharmaceuticals, Inc. NASDAQ:AERI Insiders Buy Up More Shares?

2019-11-27 09:45:31 | 5 “Strong Buy” Biotech Stocks With More Than 80% Upside

2019-11-26 06:30:00 | Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference

2019-11-22 08:18:08 | The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

2019-11-21 06:30:00 | Aerie Pharmaceuticals Receives European Commission Approval for Rhokiinsa® netarsudil ophthalmic solution 0.02%

2019-11-19 10:58:27 | Aerie buys Spanish outfit as it moves toward profitability

2019-11-19 09:31:02 | Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex

2019-11-18 06:30:00 | Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, S.L. to Advance Its Dry Eye Program

2019-11-12 07:30:00 | Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference

2019-11-07 10:51:03 | Aerie AERI Q3 Loss Wider, Sales Beat, Guidance Slashed

2019-11-07 07:18:13 | The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs